Ken Griffin Immuno Gen, Inc. Call Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 14, 2024	SELL	$12.46 - $29.95 $4,984 - $11,980	-400 Reduced 0.14%	285,000 $8.45 Million
Q3 2023 Nov 14, 2023	SELL	$14.09 - $19.87 $952,484 - $1.34 Million	-67,600 Reduced 19.15%	285,400 $4.53 Million
Q2 2023 Aug 14, 2023	SELL	$3.75 - $20.05 $174,750 - $934,330	-46,600 Reduced 11.66%	353,000 $6.66 Million
Q1 2023 May 15, 2023	BUY	$3.67 - $4.92 $687,024 - $921,024	187,200 Added 88.14%	399,600 $1.53 Million
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $202,020 - $280,164	44,400 Added 26.43%	212,400 $1.05 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $151,424 - $218,686	33,800 Added 25.19%	168,000 $803,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.